OZALIN®is a novel oral solution paediatric sedative tailored around kids
The formulation was developed at the Amiens Hospital in France, with the help of an Anaesthesiologist and a Hospital Pharmacist
Introduction to moderate sedation
Procedural burden pain and/or fear and/or anticipatory anxiety.
The sedation continuum ranges from minimal sedation to general anesthesia Ozalin is aimed at the pediatric procedural sedation market
Anxiety
• Needles
• Catheters
• Gas mask
• Surgery
Painful
• Fractures
• Sutures
• Burns
Painless
• Claustrophic
• Unmoving conditions
Endoscopy
• Fearful conditions
• Unpleasant procedures
Dental
• Needles
• Drills
• Stressful procedures
OZALIN® / OZASED®
• Launched in EU in 2018-2022 (EU rights divested in 2024).
• Utilising partners across the rest of the world to expand with the submission of regulatory files and local commercialization.
*OZALIN® / OZASED® is indicated in infants (from 6 months), children and adolescents, for moderate sedation before a therapeutic or diagnostic procedure to relieve anxiety, distress and agitation related to the procedure or as premedication before anaesthesia.
Supported by an unrestricted educational grant from Primex Pharmaceuticals
Safetots.org
Safetots.org is a non-profit initiative of leading paediatric anaesthesiologists. We promote safe conduct of anaesthesia in children.
Troops Sedation.com
A standardized quality improvement tool from the International Committee for the Advancement of Procedural Sedation.
Discover other existing Primex product portfolio
Refocol® (propofol)
• Recofol N® – propofol with MCT/LCT formulation.
• Recofol EDTA® – propofol plus EDTA.
• Propofo VET® – propofol for animals.
OGNA® Dental Portfolio
• Local Anaesthetic Portfolio – articaine, mepivicaine and lidocaine (spray & gel).
• Endodontic Medical Devices (CE marked).
